Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway
NCT ID: NCT02740114
Last Updated: 2021-10-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
105 participants
INTERVENTIONAL
2016-08-31
2020-07-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical research study is to compare the effects of bupivacaine to those of liposomal bupivacaine when given to patients who are having gynecologic surgery. Researchers want to compare how long the drugs work to numb the wound and how long patients take to recover from surgery.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 study arms:
* If you are in Arm 1, you will receive bupivacaine only.
* If you are in Arm 2, you will receive a combination of liposomal bupivacaine and bupivacaine.
You will have an equal (50/50) chance of being assigned to either group. You will not know what you are receiving. However, the study staff will know what you are receiving.
In both cases, the drug(s) will be injected into your skin and tissue at the end of your surgery, right before the wound is closed.
Study Data Collection:
Every day while you are in the hospital recovering from surgery, you will be asked questions about pain, any side effects you may be having, symptoms, and opioid use.
Within 30 days after you leave the hospital, you may also be called and asked about side effects you may be having. If you are called, this call should last about 10-15 minutes. This information may also be collected during a routinely scheduled clinic visit and from the medical record.
Three (3) and 7 days after you leave the hospital, and then 1 time every week after that for a total of 8 weeks, you will be called or emailed and asked questions about any symptoms you may be having. If you are called, each call should last about 10-15 minutes.
If you are also enrolled on the study BS99-094 "Measuring the Symptom Distress of Cancer Patients: Development of a New Assessment System," information from your participation in this study may also be collected and used in that study.
Length of Study:
Your participation on this study will be over 8 weeks after you leave the hospital.
This is an investigational study. Both bupivacaine and liposomal bupivacaine are FDA approved and commercially available. It is investigational to compare the 2 drugs.
Up to 200 participants will be enrolled in this study. All will take part at MD Anderson.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bupivacaine Group
Local wound infiltration with Bupivacaine immediately prior to wound closure during gynecological surgery.
Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
Participants complete a pill diary every day for 30 days after hospital discharge.
Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
Bupivacaine
150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.
Oxycodone
1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
Pill Diary
Participants complete a pill diary every day for 30 days after hospital discharge.
Symptom Questionnaire
Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
Liposomal Bupivacaine + Bupivacaine Group
Local wound infiltration with Liposomal Bupivacaine and 0.25% Bupivacaine admixed immediately prior to wound closure during gynecological surgery.
Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
Participants complete a pill diary every day for 30 days after hospital discharge.
Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
Bupivacaine
150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.
Liposomal Bupivacaine
266 mg injected on each side of the wound at the end of surgery before wound closure.
Oxycodone
1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
Pill Diary
Participants complete a pill diary every day for 30 days after hospital discharge.
Symptom Questionnaire
Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bupivacaine
150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.
Liposomal Bupivacaine
266 mg injected on each side of the wound at the end of surgery before wound closure.
Oxycodone
1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
Pill Diary
Participants complete a pill diary every day for 30 days after hospital discharge.
Symptom Questionnaire
Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Planned participation in the Gynecologic Enhanced Recovery Pathway
3. Female 18 years of age or older
4. Patient must be able to read and speak English
5. Consents to being part of a randomized, single-blinded study
6. Patient has physical and mental capabilities to take part in study
7. Bilirubin less than or equal to 1.5 x upper limit of the normal range (ULN); Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic-Pyruvic Transaminase (SGPT) \</=2.5 x ULN
8. If the patient is of childbearing potential, the patient must have a negative blood or urine pregnancy test within 14 days of surgical treatment on study
Exclusion Criteria
2. Patients on long-acting opioid medications, or scheduled (four or more times a day for seven or more days) short-acting opioid medications within the last 30 days
3. Emergency surgery of any type that does not allow for proper time for protocol review by the patient
4. Surgery that involves known/anticipated resection of anterior abdominal wall with plastic surgery reconstruction
5. Patients undergoing pelvic exenteration
6. Patients undergoing known/anticipated anterior abdominal wall hernia repairs
7. Patients weighing \<50 kg
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pacira Pharmaceuticals, Inc
INDUSTRY
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pedro Ramirez, MD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Meyer LA, Corzo C, Iniesta MD, Munsell M, Shi Q, Pitcher B, Lasala J, Cain KE, Wang XS, Mena G, Ramirez PT. A prospective randomized trial comparing liposomal bupivacaine vs standard bupivacaine wound infiltration in open gynecologic surgery on an enhanced recovery pathway. Am J Obstet Gynecol. 2021 Jan;224(1):70.e1-70.e11. doi: 10.1016/j.ajog.2020.07.017. Epub 2020 Jul 16.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
University of Texas MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2016-00739
Identifier Type: REGISTRY
Identifier Source: secondary_id
2015-1119
Identifier Type: -
Identifier Source: org_study_id